Biosimilars Market Analysis: US Landscape Post-Inflation Reduction Act 2026

Key Takeaways

• Market size and growth: The US biosimilars market is valued at USD 50.31 billion in 2026 and is projected to reach USD 163.14 billion by 2033, representing a compound annual growth rate (CAGR) of 18.3%.
• IRA-driven adoption: The Inflation Reduction Act has catalyzed increased biosimilar adoption through cost containment pressures and regulatory support, creating favorable conditions for market expansion.
• Manufacturer opportunities: Significant market opportunities exist for biosimilar manufacturers amid evolving regulatory frameworks and competitive landscapes, though pricing pressures and regulatory complexity remain key challenges.
• Near-term trajectory: Sustained growth through 2033 reflects ongoing healthcare cost pressures and payer incentives to shift patients toward biosimilar therapies over reference biologics.

The US biosimilars market is experiencing unprecedented expansion in 2026, driven by the Inflation Reduction Act's pricing reforms and regulatory support. Valued at USD 50.31 billion this year, the market is projected to more than triple to USD 163.14 billion by 2033, with an 18.3% CAGR reflecting sustained demand for cost-effective biologic alternatives. Why it matters: This growth trajectory signals a fundamental shift in how the U.S. healthcare system approaches biologic therapy, with biosimilars now positioned as critical cost-containment tools rather than niche alternatives.

Market Overview: Biosimilars in the US Landscape

Biosimilars are biological products highly similar to an already-approved reference biologic drug, with no clinically meaningful differences in safety, purity, or potency. Unlike generic small-molecule drugs, biosimilars require comprehensive analytical, animal, and clinical data to demonstrate comparability to their reference products. The biosimilar class encompasses therapies across multiple therapeutic areas, including oncology, immunology, endocrinology, and rheumatology, where reference biologics command significant healthcare expenditures.

The US biosimilar market encompasses approved biosimilars for a range of reference biologics, including but not limited to monoclonal antibodies (such as infliximab, adalimumab, and trastuzumab biosimilars) and growth factors. The U.S. Food and Drug Administration (FDA) has established a regulatory pathway for biosimilar approval under the Biologics Price Competition and Innovation Act, creating a structured framework for demonstrating biosimilar equivalence. This regulatory infrastructure has enabled steady market entry of biosimilar products since the first FDA-approved biosimilar in 2015.

Regulatory Context: FDA Oversight and Post-IRA Dynamics

The FDA maintains primary regulatory authority over biosimilar approvals in the United States. The agency's biosimilar approval pathway requires comparative analytical studies, animal studies, and clinical immunogenicity and pharmacokinetic/pharmacodynamic studies to establish that a proposed biosimilar is highly similar to the reference product. The FDA's guidance documents have evolved to streamline this pathway while maintaining rigorous safety and efficacy standards.

The Inflation Reduction Act, enacted in 2022, introduced significant pricing provisions affecting biologic drugs and, by extension, the biosimilar market. The IRA established Medicare's authority to negotiate drug prices, implemented rebate requirements, and created financial incentives for biosimilar development and uptake. These provisions have fundamentally altered payer strategies and formulary decisions, with health plans increasingly favoring biosimilar placement to manage costs. Compared with the pre-IRA environment, where biosimilar uptake faced prescriber hesitancy and limited payer incentives, the post-IRA landscape presents accelerated adoption driven by explicit cost-containment mandates.

What to watch next: Potential FDA policy updates to further streamline biosimilar approvals, including potential acceleration of comparative clinical trial requirements or expanded use of real-world evidence in regulatory decision-making, could further reduce time-to-market for biosimilar candidates.

Market Impact: Growth Drivers and Competitive Dynamics

The projected growth from USD 50.31 billion in 2026 to USD 163.14 billion by 2033 reflects multiple reinforcing market drivers. Cost pressures on the US healthcare system, exacerbated by rising biologic utilization, have made biosimilar adoption a strategic priority for payers. The IRA's pricing reforms and rebate structures have directly incentivized formulary placement of biosimilars, shifting patient volume away from higher-cost reference biologics.

Regulatory support post-IRA has accelerated the FDA biosimilar approval pathway, enabling faster market entry for qualified biosimilar candidates. This regulatory momentum has attracted new market entrants, including both established pharmaceutical manufacturers and emerging biosimilar-focused companies, intensifying competitive dynamics. The expanding biosimilar market has created pricing pressure across the reference biologic landscape, with reference product manufacturers responding through price adjustments, patient assistance programs, and combination therapy strategies.

The therapeutic areas with highest biosimilar penetration include rheumatology (driven by high-volume TNF-inhibitor biosimilars) and oncology (driven by trastuzumab and bevacizumab biosimilars). These areas represent significant revenue opportunities for biosimilar manufacturers, though they also face intense competitive pressures as multiple biosimilar competitors target the same reference products.

Opportunities for Biosimilar Manufacturers

The 18.3% CAGR through 2033 reflects substantial market expansion opportunities for biosimilar manufacturers. Key opportunities include:

• Expanded patient access: Increased payer coverage and formulary placement of biosimilars enable manufacturers to reach larger patient populations at lower cost barriers.
• Therapeutic area diversification: Emerging biosimilar opportunities exist in therapeutic areas with limited current biosimilar competition, including certain checkpoint inhibitors and novel biologic modalities.
• Portfolio consolidation: Strategic partnerships and acquisitions enable manufacturers to build comprehensive biosimilar portfolios, capturing market share across multiple reference products.
• Real-world evidence generation: Post-approval data collection and comparative effectiveness studies strengthen market positioning and support label expansions or new indication approvals.
• Value-based care integration: Increasing integration of biosimilars into value-based care models and accountable care organizations creates long-term contracting opportunities for manufacturers.

Challenges and Competitive Headwinds

Despite robust growth projections, biosimilar manufacturers face significant challenges in the evolving US market. Pricing competition remains intense, with multiple biosimilar competitors targeting the same reference products, driving down average selling prices. Manufacturers must navigate complex FDA regulatory requirements, including comparative clinical trial design and immunogenicity assessment, which require substantial development investment.

Prescriber hesitancy, though diminishing, remains a barrier to biosimilar adoption in certain therapeutic areas. Educational initiatives and real-world evidence generation are essential to overcome clinical concerns about biosimilar efficacy and safety. Patent litigation and reference product lifecycle management strategies by innovator companies create uncertainty around market exclusivity periods for biosimilar competitors.

Additionally, the consolidation of payer influence post-IRA has created concentrated negotiating power, potentially constraining biosimilar pricing and limiting manufacturer margins despite market volume growth.

Future Outlook: Market Trends Through 2033

The US biosimilars market is positioned for sustained expansion through 2033, with the projected USD 163.14 billion market size reflecting ongoing healthcare cost pressures and regulatory support. Several trends are expected to shape market development:

• Regulatory streamlining: Continued FDA policy evolution may further accelerate biosimilar approvals through enhanced use of comparative analytical data or real-world evidence, reducing development timelines and costs.
• Therapeutic area expansion: Biosimilar development is expected to expand into novel biologic modalities and emerging therapeutic areas, including cell and gene therapies, as regulatory frameworks evolve.
• Value-based care integration: Integration of biosimilars into outcomes-based contracting and accountable care models will drive long-term adoption and create new commercial opportunities.
• Next-generation biosimilar development: Innovation in biosimilar manufacturing, including potential development of improved formulations or combination therapies, may differentiate products in competitive markets.
• International market harmonization: Alignment of US, European, and other regulatory frameworks may facilitate global biosimilar development and reduce manufacturing complexity.

Frequently Asked Questions

References

1. Market research data on US biosimilars market valuation (USD 50.31 billion in 2026) and projected growth to USD 163.14 billion by 2033 with 18.3% CAGR, driven by cost pressures and regulatory support post-Inflation Reduction Act.

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-25.